Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest update is out from Invivyd ( (IVVD) ).
On May 15, 2025, Invivyd reported its first-quarter financial results and business highlights, noting a net product revenue of $11.3 million for PEMGARDA, influenced by a transition to an internalized sales force. The company is targeting near-term profitability by the end of the first half of 2025, supported by a strong cash position and a $30 million non-dilutive term loan facility. Despite a decline in revenue compared to the previous quarter, Invivyd observed revenue re-acceleration in Q2 2025. The company continues to focus on expanding its pipeline beyond SARS-CoV-2, with potential targets including RSV and measles. Regulatory challenges were noted, with the FDA declining to expand PEMGARDA’s emergency use authorization for certain COVID-19 treatments, but the company remains optimistic about future developments.
The most recent analyst rating on (IVVD) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Invivyd stock, see the IVVD Stock Forecast page.
Spark’s Take on IVVD Stock
According to Spark, TipRanks’ AI Analyst, IVVD is a Neutral.
Invivyd’s overall stock score reflects significant financial and technical weaknesses, marked by ongoing losses and bearish trends. While recent corporate developments offer a glimpse of potential strategic improvement, these are overshadowed by the current financial instability and weak market sentiment.
To see Spark’s full report on IVVD stock, click here.
More about Invivyd
Invivyd, Inc. operates in the biotechnology industry, focusing on the development of monoclonal antibodies for the prevention and treatment of infectious diseases. Their primary product, PEMGARDA, is an investigational monoclonal antibody authorized for emergency use for pre-exposure prophylaxis of COVID-19 in immunocompromised individuals.
Average Trading Volume: 3,217,059
Technical Sentiment Signal: Sell
Current Market Cap: $103.3M
See more data about IVVD stock on TipRanks’ Stock Analysis page.